News

BridgeBio Oncology Therapeutics reported fourth‑quarter and full‑year 2025 results and, more importantly for the market, unveiled early clinical signals...

aTyr Pharma will meet the FDA in mid-April 2026 to review mixed Phase 3 results for efzofitimod in pulmonary...

Kuva Labs has signed a definitive agreement to acquire Lisata Therapeutics via a tender offer at $5.00 per share...

UroGen Pharma has granted inducement restricted stock units to 11 new hires, covering up to 51,200 ordinary shares that...

CytomX Therapeutics will report full-year 2025 results on March 16, 2026, before U.S. market open, followed by a webcasted...

TScan Therapeutics plans to initiate its first Phase 3 trial in the second quarter of 2026 for TSC-101 to...

Kamada will report fourth-quarter and full-year 2025 results on March 11, 2026, and host an investor call that morning....

EyePoint, Inc. reported year-end 2025 results and advanced its lead asset Duravyu, a bioerodible intravitreal insert of the TKI...

AnaptysBio will separate its business into two public companies in the second quarter of 2026, potentially as early as...

Dyadic Applied Biosolutions and Denmark’s Inzymes plan to commercialize a recombinant, non-animal bovine chymosin for cheese production in 2026,...